Immunotherapy biotech unstealths with $13M; Anti-infection candidate for CF passes safety trial
Shennon Biotechnologies has raised $13 million in seed funding for a single cell platform to create more effective immunotherapies. The company says the platform can “profile millions of immune cells functionally at the single cell level within a few hours” in order to identify TCR or antibody targets.
“This technology has the potential to overcome a key bottleneck in immunotherapy by identifying rare antigen-specific immune cells through enabling high-throughput analysis of functional pairing between effector and target cells in a way that was previously impossible,” Joseph Fraietta, a scientific advisor for Shennon and director of the Solid Tumor Immunotherapy Lab at the University of Pennsylvania, said in a statement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.